MannKind Corp Appoints New Director and CMO
Ticker: MNKD · Form: 8-K · Filed: Aug 14, 2024 · CIK: 899460
| Field | Detail |
|---|---|
| Company | Mannkind CORP (MNKD) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
TL;DR
MannKind just swapped out some execs and added a new director, Dr. Michael Merz, who's now also the CMO.
AI Summary
MannKind Corporation announced on August 13, 2024, changes in its executive and director roles. The company elected Dr. Michael Merz as a new director and appointed Dr. Michael Merz as Chief Medical Officer. Additionally, Dr. Michael Merz was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee.
Why It Matters
These executive and director changes could signal a shift in the company's strategic direction or leadership focus, potentially impacting its future operations and stock performance.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty and potential shifts in strategy, which may affect the company's performance.
Key Players & Entities
- MannKind Corporation (company) — Registrant
- Dr. Michael Merz (person) — Newly elected director and Chief Medical Officer
- August 13, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for MannKind Corporation?
Dr. Michael Merz has been appointed as the new Chief Medical Officer for MannKind Corporation.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 13, 2024.
What other roles has Dr. Michael Merz taken on besides Chief Medical Officer?
Besides Chief Medical Officer, Dr. Michael Merz has also been elected as a new director and appointed to the Compensation Committee and the Nominating and Corporate Governance Committee.
What is the principal executive office address for MannKind Corporation?
The principal executive office address for MannKind Corporation is 1 Casper Street, Danbury, Connecticut 06810.
What is the SIC code for MannKind Corporation?
The Standard Industrial Classification (SIC) code for MannKind Corporation is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-14 08:03:59
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Mar
Filing Documents
- d869995d8k.htm (8-K) — 21KB
- 0001193125-24-200252.txt ( ) — 136KB
- mnkd-20240813.xsd (EX-101.SCH) — 3KB
- mnkd-20240813_lab.xml (EX-101.LAB) — 17KB
- mnkd-20240813_pre.xml (EX-101.PRE) — 11KB
- d869995d8k_htm.xml (XML) — 3KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 13, 2024 MannKind Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 1 Casper Street , Danbury , Connecticut 06810 (Address of Principal Executive Offices) (Zip Code) (818) 661-5000 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Market LLC Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b)(d) On August 13, 2024, Kent Kresa notified us of his decision to retire from our Board of Directors (the "Board"), effective September 30, 2024 (the "Effective Date"). On August 13, 2024, the Board approved the appointment of Steven B. Binder to the Board, effective on the Effective Date. Mr. Binder currently serves as our Executive Vice President, Special Projects. His employment will end concurrently with his appointment to the Board on the Effective Date. As such, Mr. Binder will be eligible to participate in our non-employee director compensation program, a copy of which is filed as Exhibit 10.15 to our Annual Report on Form 10-K, filed with the SEC on February 26, 2019. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MannKind Corporation Date: August 14, 2024 By: /s/ David Thomson David Thomson, Ph.D., J.D. Executive Vice President, General Counsel and Secretary